
Eliminating Blind Spots in the Patient Journey
The webinar, scheduled for May 22, will include executives from PurpleLab and feature Genentech Principal Informatics Systems Lead Dr. Ben Freiberg. Register today!
The webinar, scheduled for May 22, will include executives from PurpleLab and feature Genentech Principal Informatics Systems Lead Dr. Ben Freiberg. Register today!
Many healthcare AI developers lack access to real-world data. To address this, Atropos Health is allowing AI developers to train and deploy their models using its real-world evidence network. The federated healthcare data network consists of more than 300 million patient records gathered from EHRs, claims data and patient registries.
This webinar will explore how a banking platform approach could be the resource for your company.
Biomarkers, electronic health records (EHR), genomic data, imaging data, labs, social media, wearable sensors, and more provide enormous new sources of RWD that can aid in new discoveries for the quality, efficacy, and safety of new drug therapies.
CorEvitas brings Thermo Fisher Scientific registries that gather data about how approved therapies are working in the real world. The acquisition will complement PPD, the contract research organization that Thermo Fisher purchased in 2021.
FDA's draft guidances on real-world data do not provide strict requirements for industry stakeholders to abide by, but they offer patient advocacy organizations with a clearer understanding of how to model their registries to have a more substantial impact for their patient communities.
Miruna Sasu, CEO of RWE company COTA, explained that studies have shown meaningful improvements in efficiency if RWE is used in drug development and that translates into real savings. However, will such efforts continue amidst the ongoing belt-tightening in a tough economy?
In a recent interview, Jennifer Cubino, COO of BC Platforms, discussed regulatory differences between the U.S., the European Union and other countries amid ongoing efforts to encourage patients who want to share their data.
In announcing plans to offer Covid-19 booster shots, the U.S. Department of Health and Human Services cited declining vaccine efficacy shown by real-world studies. But the World Health Organization said the science is less than clear about booster shots, adding that it’s ethically wrong to give third shots when so many around the world are waiting for their first one.
In the eight months since the Gilead Sciences antiviral drug remdesivir became the first FDA-approved treatment for Covid-19, the company has been collecting real-world data about drug’s effect. The data continue to show that the drug reduces the risk of death and helps patients get discharged from the hospital sooner.
The startup will work with the FDA to evaluate the efficacy and safety of current cancer treatments in different groups of cancer patients.
Can an industry coalition help craft policy to support the use of Real-World Evidence? Five prominent real-world data and analytics companies are betting on it, launching the RWE Alliance.
Evidation, launched as a research app where people can opt into virtual clinical trials, now plans to offer digital health programs. The company recently raised $153 million in new funding.
The companies will use a combination of more than seven years of medical record data with five years of prospective data on 5,000 MS patients, including real-world outcomes data and MRI images. Other disease areas to be explored include hematology and rare diseases.
The two plan to identify and analyze sources of real-world data that they can use to characterize populations of patients with Covid-19, their use of medicines, risk factors and to characterize potential interventions.
The health technology assessment group and the New York-based company announced their partnership Monday. ICER also plans to use RWE in assessing drugs that have accelerated FDA approval.